Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This was a multicenter, open-label, phase I/II study to evaluate the safety and tolerability,
radiation dosimetry and pharmacokinetic characteristics, and efficacy of [177Lu] Lu-XT033
injection in patients with metastatic prostate cancer, including a phase I study and a phase
II extension study.